Filtered By:
Specialty: Cardiology
Condition: Diabetes Type 2

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 574 results found since Jan 2013.

Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease after acute myocardial infarction
Chen et al. evaluated the cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in 1025 type 2 diabetic patients with chronic kidney disease (CKD) after acute myocardial infarction (AMI) [1]. The authors set the primary outcomes as myocardial infarction, ischemic stroke or cardiovascular death, and they conducted a one-year follow-up with use of the Cox proportional hazard models. Although, the use of sitagliptin was not associated with an increased risk of cardiovascular death, ischemic stroke or hospitalization for heart failure, hazard ratios (95% confidence intervals) of sitagli...
Source: International Journal of Cardiology - September 13, 2015 Category: Cardiology Authors: Tomoyuki Kawada Tags: Correspondence Source Type: research

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin Cardiovascular Outcomes in the EXAMINE Trial
Activation of the sympathetic nervous system when there is dipeptidyl peptidase 4 inhibition in the presence of high-dose angiotensin-converting enzyme (ACE) inhibition has led to concerns of potential increases in cardiovascular events when the 2 classes of drugs are coadministered. We evaluated cardiovascular outcomes from the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin versus Standard of Care) trial according to ACE inhibitor use. Patients with type 2 diabetes mellitus and a recent acute coronary syndrome were randomly assigned to receive the dipeptidyl peptidase 4 inhibitor alogliptin or placebo add...
Source: Hypertension - August 9, 2016 Category: Cardiology Authors: White, W. B., Wilson, C. A., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Heller, S. K., Mehta, C. R., Nissen, S. E., Zannad, F., Kupfer, S., for the EXAMINE Investigators Tags: Heart Failure, Myocardial Infarction, Complications, Mortality/Survival Cardiovascular Outcomes in the EXAMINE Trial Source Type: research

Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance Clinical Trial
Orthostatic hypotension (OH) is associated with hypertension and diabetes mellitus. However, in populations with both hypertension and diabetes mellitus, its prevalence, the effect of intensive versus standard systolic blood pressure (BP) targets on incident OH, and its prognostic significance are unclear. In 4266 participants in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) BP trial, seated BP was measured 3x, followed by readings every minute for 3 minutes after standing. Orthostatic BP change, calculated as the minimum standing minus the mean seated systolic BP and diastolic BP, was assessed at baseline...
Source: Hypertension - September 6, 2016 Category: Cardiology Authors: Fleg, J. L., Evans, G. W., Margolis, K. L., Barzilay, J., Basile, J. N., Bigger, J. T., Cutler, J. A., Grimm, R., Pedley, C., Peterson, K., Pop-Busui, R., Sperl-Hillen, J., Cushman, W. C. Tags: Hypertension Clinical Trial Source Type: research

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor AlogliptinNovelty and Significance Cardiovascular Outcomes in the EXAMINE Trial
Activation of the sympathetic nervous system when there is dipeptidyl peptidase 4 inhibition in the presence of high-dose angiotensin-converting enzyme (ACE) inhibition has led to concerns of potential increases in cardiovascular events when the 2 classes of drugs are coadministered. We evaluated cardiovascular outcomes from the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin versus Standard of Care) trial according to ACE inhibitor use. Patients with type 2 diabetes mellitus and a recent acute coronary syndrome were randomly assigned to receive the dipeptidyl peptidase 4 inhibitor alogliptin or placebo add...
Source: Hypertension - August 9, 2016 Category: Cardiology Authors: White, W. B., Wilson, C. A., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Heller, S. K., Mehta, C. R., Nissen, S. E., Zannad, F., Kupfer, S. Tags: Heart Failure, Myocardial Infarction, Complications, Mortality/Survival Original Articles Source Type: research

A new era in the management of type 2 diabetes: is cardioprotection at long last a reality!
The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo. Liraglutide, a GLP-1 analogue, succeeded to demonstrate reduction on a composite outcome including first occurrence of cardiovascular death, nonfatal myocardial infarction or non-fatal stroke. These two medications act through different mechanisms and has consequently shown different patterns of cardiovascular benefit.
Source: International Journal of Cardiology - November 11, 2016 Category: Cardiology Authors: Xavier Rossello, Derek M. Yellon Tags: Editorial Source Type: research

A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo. Liraglutide, a GLP-1 analogue, succeeded to demonstrate reduction on a composite outcome including first occurrence of cardiovascular death, nonfatal myocardial infarction or non-fatal stroke. These two medications act through different mechanisms and has consequently shown different patterns of cardiovascular benefit.
Source: International Journal of Cardiology - November 11, 2016 Category: Cardiology Authors: Xavier Rossello, Derek M. Yellon Tags: Editorial Source Type: research

Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials
ConclusionIn patients with type 2 diabetes, the safety profile of DPP-4 inhibitors is similar to placebo. As a class, there is only weak evidence for an increased risk of heart failure.
Source: American Journal of Cardiovascular Drugs - November 20, 2016 Category: Cardiology Source Type: research

Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews
Conclusion: The available evidence supports treatment in people with type 2 diabetes and SBP more than 140 mmHg, using any of the major antihypertensive drug classes.
Source: Journal of Hypertension - January 31, 2017 Category: Cardiology Tags: Reviews Source Type: research

Serial Measurement of High Sensitivity Troponin I and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus in the EXAMINE Trial.
Conclusions -Serial assessment of hsTnI revealed a substantial proportion of patients with T2DM without clinically recognized events had dynamic or persistently elevated values and were at high risk of recurrent events. hsTnI may have a role in personalizing preventive strategies in patients with diabetes based on risk. Clinical Trial Registration -https://clinicaltrials.gov Identifier: NCT00968708. PMID: 28246236 [PubMed - as supplied by publisher]
Source: Circulation - February 27, 2017 Category: Cardiology Authors: Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA Tags: Circulation Source Type: research

Association between carotid plaque characteristics and acute cerebral infarction determined by MRI in patients with type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) might aggravate the carotid plaque vulnerability, and increase the risk for ischemic stroke. Few studies reported the acute stroke subtype with carotid plaque characteristics in...
Source: Cardiovascular Diabetology - September 11, 2017 Category: Cardiology Authors: Beibei Sun, Xiao Li, Xiaosheng Liu, Xiaoqian Ge, Qing Lu, Xihai Zhao, Jun Pu, Jianrong Xu and Huilin Zhao Tags: Original investigation Source Type: research

Is white rice consumption a risk for metabolic and cardiovascular outcomes? A systematic review and meta-analysis
Conclusions Higher white rice consumption has not been shown to be associated with increased risk of CHD, stroke and T2DM. However, white rice consumption may be associated with increased risk of MetS in certain populations
Source: Heart Asia - August 31, 2017 Category: Cardiology Authors: Krittanawong, C., Tunhasiriwet, A., Zhang, H., Prokop, L. J., Chirapongsathorn, S., Sun, T., Wang, Z. Tags: Original research Source Type: research

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
CONCLUSIONS : Patients with type 2 diabetes mellitus and prior cardiovascular events had higher rates of cardiovascular outcomes compared with the primary prevention patients. Canagliflozin reduced cardiovascular and renal outcomes with no statistical evidence of heterogeneity of the treatment effect across the primary and secondary prevention groups. Additional studies will provide further insights into the effects of canagliflozin in these patient populations. CLINICAL TRIAL REGISTRATION : URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01032629 and NCT01989754. PMID: 29133604 [PubMed - as supplied by publisher]
Source: Circulation - November 13, 2017 Category: Cardiology Authors: Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, CANVAS Program Collaborative Group Tags: Circulation Source Type: research

Glycogen synthase kinase 3 β helps heart to pump better in obese patients
Obesity is a growing problem worldwide and is associated with a wide range of comorbidities such as type-2 diabetes (T2D), rheumatoid arthritis, cognitive impairment and dementia, hypertension, stroke and heart failure [1]. The global obesity pandemic affects all age groups. A recent study, based on body mass index (BMI) in over 68 million subjects from 195 countries, suggests that prevalence of metabolic diseases was increased in high BMI subjects globally in the past 20  years [2]. The increased BMI has been shown to be pathogenically related to several diseases including cardiovascular and stroke-related diseases [3].
Source: International Journal of Cardiology - March 23, 2018 Category: Cardiology Authors: Suresh Kumar Verma Source Type: research

Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women Original Articles
Conclusions: Circulating plasma BCAAs were positively associated with incident CVD in women. Impaired BCAA metabolism may capture the long-term risk of the common cause underlying T2D and CVD.
Source: Circulation: Cardiovascular Genetics - March 23, 2018 Category: Cardiology Authors: Tobias, D. K., Lawler, P. R., Harada, P. H., Demler, O. V., Ridker, P. M., Manson, J. E., Cheng, S., Mora, S. Tags: Biomarkers, Cardiovascular Disease, Diabetes, Type 2, Epidemiology, Women Original Articles Source Type: research

The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE) –TIMI 58 Trial
Conclusion The DECLARE–TIMI 58 trial is testing the hypotheses that dapagliflozin is safe (does not increase) and may reduce the occurrence of major CV events. DECLARE–TIMI 58 is the largest study to address this question with an SGLT-2 inhibitor in patients with T2DM and with established CV disease and without CV disease but with multiple risk factors.
Source: American Heart Journal - May 8, 2018 Category: Cardiology Source Type: research